Rabbit Polyclonal CHRFAM7A Antibody

The CHRFAM7A gene, a human-specific fusion of CHRNA7 (encoding the α7 subunit of the nicotinic acetylcholine receptor, α7-nAChR) and a partial duplication of ULK4. produces a uniquely human protein variant. CHRFAM7A antibodies are critical tools for studying this isoform, which differs from the ancestral α7-nAChR by a 27-amino acid duplication and altered receptor function. The gene is polymorphic, with a common 2-bp deletion (Δ2bp) linked to altered expression and potential disease associations. CHRFAM7A is co-expressed with α7-nAChR in immune cells, neurons, and epithelial tissues, where it may form heteromeric receptors or act as a dominant-negative modulator, influencing cholinergic signaling, inflammation, and neuropsychiatric processes. Antibodies targeting CHRFAM7A enable detection of its expression patterns, interaction dynamics, and functional roles in conditions like schizophrenia, Alzheimer’s disease, and inflammatory disorders. Its human-specificity highlights evolutionary divergence in cholinergic pathways, necessitating species-specific research models. Commercial CHRFAM7A antibodies are typically validated for Western blot, immunohistochemistry, or flow cytometry, though cross-reactivity with α7-nAChR requires careful epitope selection. Research using these antibodies contributes to understanding human-specific neuroimmune mechanisms and therapeutic targeting of α7-related pathways.